CN

about us

about us
Doma is an innovative biotechnology company with an independent drug research and development pipeline that aslo functions as a biotech incubator with flexible and diverse operation models. Our goal is to gather top biotech talents and promising enterpreneurs to extablish an extensive presence in the most cutting-edge fields of biotechnology.
More

Shareholders

company

Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

China Life Healthcare Investment

China Life Private Equity Investment Co., Ltd.

PICC Capital

PICC Capital Insurance Asset Management Co., Ltd.

SDIC Venture Capital

SDIC Venture Capital Co., Ltd.

Oriza Holdings

Oriza Holdings

Harvi Capital

Suzhou Harvi Capital Management Co.,Ltd.

Lingjun Venture Capital

Suzhou Industrial Park Lingjun Venture Capital Co., Ltd.

Taiping Healthcare Fund

Taiping Healthcare Industry Equity Investment Fund

CMB International

China Merchants International Finance Co., LTD

Shareholders

company

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is an international biopharmaceutical company that drives the research and development of novel fully human antibody-based drugs using innovative technologies.  Biocytogen is committed to technological innovation to become a global birthplace of novel drugs to safeguard human health.

More

China Life Private Equity Investment Co., Ltd.

Founded in June 2016, China Life Private Equity Investment Co., Ltd. is a specialized private equity investment platform and a subsidiary of China Life. In 2016, the company launched the China Life Healthcare Fund, which is a leading flagship fund in China’s healthcare industry, and the first approved private equity fund sponsored by insurance capital following the issuance of relevant policies by China Insurance Regulatory Commission.

More

PICC Capital Insurance Asset Management Co., Ltd.

PICC Capital Insurance Asset Management Co., Ltd. is a wholly owned subsidiary of The People's Insurance Company (Group) Of China Limited (601319.SH, 1339.HK). The company invests in a wide range of sectors such as energy resources, infrastructure, science and technology innovation, and healthcare to generate long-term returns for institutional investors.


More

SDIC Venture Capital Co., Ltd.

Founded in 2016, SDIC Venture Capital Co., Ltd. (SDIC Venture Capital) is a fund management company independently managed by the State Development and Investment Corp. under a market-based governance structure. Currently, the company manages assets valued at a total of RMB 22 billion. With the aim of “serving the national innovation strategy and focusing on the transformation of scientific and technological achievements”, SDIC Venture Capital carefully balances its goals of policy orientation and return on investment in its innovative practice of exploring the industrialization of scientific and technological achievements, thus effectively implementing the national development strategy while achieving a win-win situation for the government, society, and the market.

More

Oriza Holdings

Oriza Holdings is a state-owned investment holding company controlled by Suzhou Industrial Park Administrative Committee with equity participation from Jiangsu Guoxin Group. Its business covers three major sectors: equity investment, debt financing, and investment and financing services. Among them, equity investment is the most important business segment for Oriza Holdings. After years of focused and in-depth development in this segment, the company has grown into a first-class equity investment institution in China, with a current managed fund size of over RMB 100 billion.

More

Suzhou Harvi Capital Management Co.,Ltd.

Suzhou Harvi Capital Management Co.,Ltd. (Harvi Capital) is a fund management company approved by the Party Working Committee and the Management Committee of Suzhou Industrial Park. Harvi Capital manages a total fund size of RMB 12 billion, including 10 billion of government-led industry-oriented funds and 2 billion of angel master funds. The Harvi Capital team comprises of members hailing from well-known domestic institutions, with strong industrial background and rich investment experience. Through direct investment and master fund investment, Harvi Capital gives full play to the driving role of industrial guidance funds and angel master funds, promotes the implementation and development of projects in the key industrial directions of the park, and help accelerate the construction of a world-class high-tech industrial park.

More

Suzhou Industrial Park Lingjun Venture Capital Co., Ltd.

Established in December 2012, Suzhou Industrial Park Lingjun Venture Capital Co., Ltd. (Lingjun Venture Capital) is an angel investment company approved by Suzhou Industrial Park Administrative Committee, and is 100% owned by Suzhou Industrial Park Enterprise Development Service Center. With a registered capital of RMB 307.5 million, Lingjun Venture Capital mainly invests in early-stage technology-based projects with a focus on emerging industries such as artificial intelligence, healthcare, and nanotechnology applications, to accelerate the growth of enterprises and facilitate government-led science and technology innovation.

More

Taiping Healthcare Industry Equity Investment Fund

Taiping Healthcare Industry Equity Investment Fund is managed by Taiping Innovation Investment, a private equity firm under China Taiping Insurance Group. Taiping Healthcare Fund has successfully registered with the Insurance Asset Management Association of China and the Asset Management Association of China. The fund has a registered size of RMB 10 billion, of which RMB 5 billion has been contributed by Taiping Life Insurance. The fund will adopt a combination of direct and indirect investment strategies, focusing on sectors including biopharmaceuticals and pharmaceutical outsourcing, medical devices and diagnostics, medical services, biotechnology and medical information technology, radiological health technology and healthcare expenditure.

More

China Merchants International Finance Co., LTD

China Merchants International Finance Co., LTD (CMB International) is a comprehensive, professional, and integrated financial service provider based in Hong Kong, with strong roots in the Mainland and a global perspective, and is a wholly-owned subsidiary of China Merchants Bank Co.,Ltd. The company has established major business lines including asset management products and dedicated wealth management business with extensive investment in Asia-Pacific and global secondary markets, cross-border business (QFII, etc.), project direct investment business (equity, debt, etc.), and investment advisory business. The product lines cover a series of funds such as equity, bond, FOF, quantitative investments, and PE, as well as various customized products for special accounts.

More

Incubatees

company

Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

Xadcera is an innovative biotechnology company based in China with a global perspective, which focuses on the development of innovative dual anti-ADC drugs with proprietary intellectual property rights.
More

Xaicure Pharmaceuticals (Suzhou) Co., Ltd.

Xaicure is an innovative biopharmaceutical company focused on the preclinical and clinical development of small molecule targeted drugs, with a research emphasis on cancer treatment.
More

news

news
More
2024/08/29

Doma’s bispecific ADC(EGFR/c-MET) DM005,has received US FDA IND clearance

On August 29th, 2024, Doma’s second bispecific ADC asset, DM005, officially received IND clearance from U.S. FDA and about to begin global phase Ⅰ trial.
more
2024/07/04

Doma's bispecific ADC, DM001, has received US FDA IND clearance

On July 4th, 2024, Doma and its affiliate, Xadcera, officially received IND clearance from U.S. FDA for their first bispecific ADC asset, DM001. Prior to that, Doma also officially obtained CTN approval from Australia on Jun 26th, which indicates DM001 global phase Ⅰ trial is coming.
more
2024/01/29

Doma Appoints Dr. Jun Song as Chief Strategy Officer

On January 29, 2024, Beijing Time, Doma announced the appointment of Dr. Jun Song as the company's chief strategy officer. Dr. Song assumes the role of leading Doma's strategic and product line planning and the expansion of international collaborations for the company's pipelines.
more
2022/07/18

Raising 950 million yuan to establish China's pharmaceutical "Flagship", Doma Biopharmaceutical innovated in industry incubation.

Doma Biopharmaceutical is dedicated to becoming China's "Flagship" and fostering a "fully integrated life science innovation and incubation platform". This platform seamlessly integrates talent, technology, industry expertise, and capital to nurture exceptional innovative technology companies and make substantial contributions to the sustainable development of healthcare sector, and human well-being.
more
2022/06/01

Doma Raises RMB 950 Million Series A Financing to Incubate Innovative Life Sciences Companies

On June 1, 2022, Doma Biopharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as "Doma") announced the closing of a Series A financing round of RMB 950 million.
more
2021/10/20

Doma landed in BioBAY to jointly create new drug research and development innovation highland

On October 20, Doma announced the official start of its operation and plans to build its new drug development headquarters in Suzhou Industrial Park. Doma was established in Suzhou BioBAY in September 2021. Led by Biocytogen and supported by three major central enterprises, China Life, PICC and State Development and Investment Corp., as well as CMB International and Suzhou Industrial Park, the project involves the joint construction of an innovative drug incubation center and the investment of the first phase is expected to exceed RMB 1 billion.
more

Doma’s bispecific ADC(EGFR/c-MET) DM005,has received US FDA IND clearance

2024/08/29

Doma's bispecific ADC, DM001, has received US FDA IND clearance

2024/07/04

Doma Appoints Dr. Jun Song as Chief Strategy Officer

2024/01/29

Raising 950 million yuan to establish China's pharmaceutical "Flagship", Doma Biopharmaceutical innovated in industry incubation.

2022/07/18

Doma Raises RMB 950 Million Series A Financing to Incubate Innovative Life Sciences Companies

2022/06/01

Doma landed in BioBAY to jointly create new drug research and development innovation highland

2021/10/20
more

Management Team

team
More

Dr. Rong Chen

Chief Medical Officer

Dr. Rui Huang

Chief Operating Officer

Dr. Jun Song

Chief Strategy Officer

Dr. Rong Chen

Chief Medical Officer

Dr. Chen has more than 30 years experience in pharmaceutical industry, including Eucure, Citrine Medicine, JHL Biotech, Sanofi, Bayer Schering Pharma and GSK, with broad experiences from drug clinical development, drug evaluation, regulatory affairs, medical affairs and drug safety. He received Florey Followship of Roayal Adelaide Hospital, and research fund from NHM & RC of Australia. He worked in the Therapeutic Goods Administration of Australia for drug evaluation and registration. 


Dr. Rui Huang

Chief Operating Officer

Dr. Huang joined Doma in December 2022 and has extensive experience in R&D and management. Prior to joining Doma, she served as the Technical Director of Gene Editing Department and Senior Director of Preclinical Pharmacology and Pharmacodynamics Department at Biocytogen Pharmaceuticals (Beijing) Co., Ltd.. Dr. Huang received her B.S. degree in Biology from Henan Normal University in July 2006 and her Ph.D. degree in Biochemistry and Molecular Biology from the Academy of Military Medical Sciences of the PLA Academy of Military Science in June 2011.

Dr. Jun Song

Chief Strategy Officer

Dr. Song joined Doma in Jan 2024. Prior to that, Dr. Song held positions as Head of NIBR Business Development & Licensing (China) and Executive Director at Novartis. She has also held important positions at Sandoz US, Meda China and Pfizer China. Dr. Song has several years of experience as a practicing clinical physician. Dr. Song obtained her Ph.D. degree in 2007 from Medical College of Ohio (now the University of Toledo) in United States, majoring in Cellular and Molecular Biology and minor in Bioinformatics.

More